Il programma della giornata congressuale si articola in tre Sessioni.

PrimoLa Prima Sessione è dedicata ai Presupposti Clinici alla Vaccinazione, ed è preceduta da una Main Lecture di Xavier Bosch sui 10 anni trascorsi di programmi vaccinali ("The first decade of HPV vaccination and perspectives of upcoming strategies: nonavalent vaccine and FASTER study") e chiusa da un'altra Main Lecture a cura di Maria Kyrgiou sugli esiti ostetrici della conizzazione ("Obstetrical outcomes of conization"). 

Tra le due Lectures si entra nel dettaglio delle lesioni HPV-correlate, con la relazione di Paolo Giorgi Rossi sulla "Dimensione dell'infezione da HPV: genotipi prevalenti e trend storico in Europa e Italia", di Barbara Suligoi con la presentazione su "Incidenza e prevalenza della condilomatosi genitale: i dati italiani nel panorama mondiale" ed infine di Silvano Costa con la "Patologia neoplastica del tratto ano-genitale maschile e femminile".

SecondoLa Seconda Sessione è incentrata su Vaccinazione: attualità e prospettive con HPV-9, ed inizia con il punto di Gianni Rezza sulla "Vaccinazione come promozione dell'equita sociale", per continuare con Paolo Bonanni ed i dettagli del "Programma organizzato in Italia: adesione e implementazione della vaccinazione HPV", e quindi Rosa De Vincenzo, entrando nel merito della "Estensione della vaccinazione HPV ad altri setting: donna adulta e post-terapia". Maria Teresa Sandri seguirà con "Quali test di screening nelle vaccinate" e Massimo Origoni con  "Il razionale della vaccinazione maschile". La sessione si conclude con Alberto Villani che affronta un tema fondamentale per il successo del programma vaccinale, cioè "Le sinergie con il pediatra: un passaggio irrinunciabile", per chiudere infine con Luciano Mariani che relaziona sulla novità del vaccino nonavalente  "Il ruolo della protezione diretta multivalente: il vaccino nonavalente ed i benefici attesi".

TerzoDopo la pausa per il lunch, la Terza Sessioneè dedicata ad alcune delle numerose Tematiche Controverse. Inizia Aldo Venuti con un il tema innovativo dei "Vaccini terapeutici: lo stato dell’arte", per passare poi alla pagina attualissima delle"Evidenze e controversie in tema di fertilità di coppia e HPV" dibattuto da Antonio Perino.

La Sessione prosegue quindi con uno spazio dedicato alla patologia HPV-correlata dell'orofaringe con le relazioni di Giuseppe Spriano "HPV e orofaringe: epidemiologia descrittiva" e di Giuseppe Sanguineti "De-intensificazione terapeutica  nel cancro orofaringeo HPV-correlati: a che punto siamo?.  Il congresso termina con le presentazioni di Mario Preti "Carcinogenesi vulvare: HPV, ma non solo", di Maria Benevolo "Cancro dell’ano: alla ricerca di uno screening HPV-based" ed infine di Paolo Cristoforoni su un tema così delicato come il "Comunicare la sicurezza vaccinale: tra evidenze e disinformazione".

 

 

 

Bibliografia generale

Nella presente Sezione sono elencati alcuni articoli correlati allo studio sull'HPV, ed in particolare sulla vaccinazione. Gli articoli proposti rappresentano solo uno spunto per approfondire le materie trattate nel Congresso e, molti di loro, sono il frutto del lavoro dei Relatori presenti.

 

Riccardo Audisio et al. Public health value of universal HPV vaccination.

X Castellsague' et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer (2011) 105, 28 – 37

Graham R Leggatt and Ian H Frazer. HPV vaccines: the beginning of the end for cervical cancer. Current Opinion in Immunology 2007, 19:232–238

Maria Benevolo et al. Interobserver Reproducibility of Cytologic p16INK4a=Ki-67 Dual Immunostaining in Human Papillomavirus-Positive Women. Cancer Cytopathology (2016)

Paolo Bonanni et al. An overview on the implementation of HPV vaccination in Europe. Human Vaccines 7: Supplement, 128-135; January/February 2011;Human Vaccines 7: Supplement, 128-135; January/February 2011;

F. Xavier Bosch et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. NATURE REVIEWS | CLINICAL ONCOLOGY VOLUME 13 | FEBRUARY 2016 | 119

Silvano Costa et al. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. ecancer 2015, 9:528 DOI: 10.3332/ecancer.2015.528

Rosa De Vincenzo et al. Long-term efficacy and safety of human papillomavirus vaccination. International Journal of Women’s Health 2014:6 999–1010

Maria Gabriella Dona et al. Mucosal and cutaneous human papillomaviruses in head and neck squamous cell papillomas. Head Neck 39: 254–259, 2017

Mélanie Drolet et al. Population-level impact and herd eff ects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15: 565–80

Nicolas Wentzensen et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer 2016 Dec 22. doi: 10.1002/ijc.30579.

The FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med 2007; 356:1915-27.

Suzanne M. Garland et al.  Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Disease 2016 Aug 15;63(4):519-27.

Paolo Giorgi Rossi et al. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infectious Agents and Cancer 2012, 7:26

Anna R. Giuliano et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med 2011;364:401-11.

Rolando Herrero et al.  Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS One. 2013 Jul 17;8(7):e68329

Elmar A Joura et al.  Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–702

Elmar A Joura et al.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401 doi: 10.1136/bmj.e1401

Elmar A Joura et al.  A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in Women. N Engl J Med 2015; 372:711-2

Maria Kyrgiou et al.  Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014;349:g6192 doi: 10.1136/bmj.g6192

Maria Kyrgiou et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia (Review). Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD008478.

Douglas R. Lowy and John T. Schiller. Reducing HPV-Associated Cancer Globally. Cancer Prev Res; 5(1) January 2012

Luciano Mariani et al. Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review. Adv Ther (2015) 32:10–30

Luciano Mariani et al.  Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynecol Obstet 2017; 1–8

Lauri E. Markowitz et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. PEDIATRICS Volume 137 , number 3 , March 2016

Silvia Massa, Aldo Venuti et al. A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2017, VOL. 13, NO. 2, 1–122017, VOL. 13, NO. 2, 1–12

Nubia Muñoz et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348:518-27.

Massimo Origoni et al. Cervical Cancer Prevention: New Frontiers of Diagnostic Strategies.  BioMed Research International Volume 2015, Article ID 250917

J. Paavonen et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): fi nal analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301–14

Joel M. Palefsky et al. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. N Engl J Med 2011;365:1576-85.

Aldo Venuti et al.  HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 2, 1–72017, VOL. 13, NO. 2, 1–7

Mario Preti et al. VIN usual type—from the past to the future. ecancer 2015, 9:531 DOI: 10.3332/ecancer.2015.531

M Teresa Sandri et al. HPV self-sampling in CIN2+ detection: sensitivity and specificity of different RLU cut-off of HC2 in specimens from 786 women.   J Clin Pathol 2016;0:1–4. doi:10.1136/jclinpath-2016-204044

Mario Sideri, Paolo Cristoforoni et al. Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series. Vaccine 27 (2009) A30–A33

S Rachel Skinner et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014; 384: 2213–27

Margaret Stanley. HPV vaccination in boys and men. Human Vaccines & Immunotherapeutics 10:7, 2109–2111; July 2014.

Carlo Maria Stigliano et al. HPV: Evidenze e nuove prospettive. Rivista di ostetricia ginecologia pratica e medicina perinatale. Vol.XXXI, n.1, 2016 

Barbara Suligoi et al. Prevalence and incidence of external genital warts in a sample of Italian general female population. BMC Infectious Diseases (2017) 17:126

Simona Venturoli, Silvano Costa et al. Time to viral clearance after successful conservative treatment for high-risk HPV–infected high-grade cervical intraepithelial neoplasia and early invasive squamous cervical carcinoma. Diagnostic Microbiology and Infectious Disease 86 (2016) 270–272

Aldo Venuti et al. Immunotherapy of HPV‐associated cancer: DNA/plant‐derived vaccines and new orthotopic mouse models. Cancer Immunol Immunother (2015) 64:1329–1338

Patrizia Vici et al.  Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. EXPERT REVIEW OF VACCINES, 2016 VOL. 15, NO. 10, 1327–1336VOL. 15, NO. 10, 1327–1336

Harald zur Hausen. Papillomavirus infections - a major cause of human cancers. Biochimica et Biophysica Acta 1288 (1996) F55-F78

Harald zur Hausen. Papillomaviruses and cancer: from basic studies to clinical applicatiion. Nature Reviews and Cancer.vol2, 2002, 342-350

Jan M. Walboomers et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189: 12–19 (1999)J. Pathol. 189: 12–19 (1999)